NKTR
NEKTAR THERAPEUTICS
NASDAQ · Healthcare · Biotechnology · US
$67.10
−1.84%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$2.13
- Revenue estimate
- $10.3M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$1.23
- EPS estimate
- -$1.97
- Revenue actual
- $10.1M
- Revenue estimate
- $10.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +24.0%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $166
- PT range
- $153 – $178
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$1.97 | -$1.23 | Beat 37.56% | $10.1M |
| May 7, 2026 | -$1.74 | -$1.82 | Miss -4.60% | $10.9M |
| Mar 12, 2026 | -$2.47 | -$1.78 | Beat 28.05% | $21.8M |
| Nov 6, 2025 | -$2.85 | -$1.85 | Beat 35.09% | $11.8M |
| Aug 7, 2025 | -$3.13 | -$2.95 | Beat 5.75% | $11.2M |
| May 8, 2025 | -$2.70 | -$3.30 | Miss -22.22% | $10.5M |
| Mar 12, 2025 | -$1.95 | -$2.25 | Miss -15.38% | $29.2M |
| Nov 7, 2024 | -$0.23 | -$0.18 | Beat 21.74% | $24.1M |
| May 9, 2024 | -$0.21 | -$0.18 | Beat 14.29% | $21.6M |
| Mar 4, 2024 | -$0.20 | -$0.22 | Miss -10.00% | $23.9M |
| Feb 28, 2023 | -$0.45 | -$0.32 | Beat 28.89% | $22.0M |
| Nov 3, 2022 | -$0.47 | -$0.24 | Beat 48.94% | $23.6M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026